BioCentury | Mar 27, 2014
Targets & Mechanisms

Insights into ependymoma

...none of the posterior fossa group B tumors. The genes were cysteine-rich protein 1 ( CRIP1...
BioCentury | Sep 25, 1995
Clinical News

Somatix regulatory update

The Alameda, Calif., company said that the Whitehead Institute received U.S. Patent No. 5,449,614 covering the use of a packaging cell line to produce non-replicating retroviral vectors for human gene therapy. The technology is exclusively...
Items per page:
1 - 2 of 2